GSK focuses on emerging markets as European austerity bites
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline's strategy of increasing its top-line exposure to emerging markets looked wise today as the UK pharma giant reported that austerity measures imposed by European governments had dented its European sales growth by six percentage points in the second quarter.